JAMP-METHOTREXATE SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

METHOTREXATE (METHOTREXATE SODIUM)

Prieinama:

JAMP PHARMA CORPORATION

ATC kodas:

L01BA01

INN (Tarptautinis Pavadinimas):

METHOTREXATE

Dozė:

25MG

Vaisto forma:

SOLUTION

Sudėtis:

METHOTREXATE (METHOTREXATE SODIUM) 25MG

Vartojimo būdas:

INTRA-ARTERIAL

Vienetai pakuotėje:

2ML/40ML

Recepto tipas:

Prescription

Gydymo sritis:

ANTINEOPLASTIC AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0107545002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2022-11-14

Prekės savybės

JAMP-METHOTREXATE, METHOTREXATE INJECTION USP, 25 MG/ML UNPRESERVED
PAGE 1 OF 69
PRODUCT MONOGRAPH
Pr
Jamp-METHOTREXATE
Methotrexate Injection USP
Unpreserved
Methotrexate 25 mg/mL
Sterile Solution
ANTIMETABOLITE AND ANTIRHEUMATIC JAMP PHARMA CORPORATION DATE OF REVISION
:
September 25, 2019
1310 rue Nobel
Boucherville, Québec
Canada J4B 5H3
SUBMISSION CONTROL NO.:
230627
JAMP-METHOTREXATE, METHOTREXATE INJECTION USP, 25 MG/ML UNPRESERVED
PAGE 2 OF 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
..........................................................................................................
12
DRUG INTERACTIONS
..........................................................................................................
15
DOSAGE AND ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 28
STORAGE AND
STABILITY..................................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 32
PART II: SCIENTIFIC INFORMATION
.......................................